Comment from Cleveland Clinic

Summary: Cleveland Clinic, a non-profit healthcare system, strongly supports the FDA's initiative to use AI to improve the efficiency and safety of early-phase clinical trials. They advocate for a staged implementation approach that emphasizes longitudinal data analysis, human-in-the-loop oversight, and on-premise deployment to ensure data privacy and clinical integration.